Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cremer Oleo GmbH & Co. Kg has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single active matter is assigned to 1 distinct examiner within 1 distinct art unit, reflecting a highly focused prosecution state. For a portfolio of this size, the administrative footprint is minimal, as all current patent office interaction is concentrated in a single point of contact.
The busiest examiner for the company is MOREAU, NASHARA LOUISE, who is responsible for the 1 pending office action. This means that all of the company's current pending actions are under the review of this specific individual. Practitioners must focus their strategy entirely on the preferences and past decisions of this 1 examiner, as there are no other active examiners or art units to provide a comparative baseline for the company's current experience.
The concentration of 1 pending action in 1 art unit suggests that the company's current legal efforts are specialized rather than diversified across multiple pharmaceutical categories. Because there is only 1 examiner involved, the prosecution outcome for the entire pending portfolio depends on a single relationship. This streamlined structure simplifies docketing but increases the impact of an individual examiner's discretion on the company's immediate patent goals.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOREAU, NASHARA LOUISE | 1 | 66.7% | -80.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18555048 | METHOD FOR PRODUCING PEPTONES COMPRISING PROTEINS AND AMINO ACIDS FROM MUCOUS MEMBRANES OF ANIMALS TO BE SLAUGHTERED, AND THE PEPTONES THEMSELVES | MOREAU, NASHARA LOUISE | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18555048 | METHOD FOR PRODUCING PEPTONES COMPRISING PROTEINS AND AMINO ACIDS FROM MUCOUS MEMBRANES OF ANIMALS TO BE SLAUGHTERED, AND THE PEPTONES THEMSELVES | MOREAU, NASHARA LOUISE | 1655 | §103§112 | Non-Final OA | — | Pending | Oct 12, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCremer Oleo GmbH & Co. Kg has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Nashara Louise Moreau has the most, with 1 of Cremer Oleo GmbH & Co. Kg's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
